Scancell Plc logo

Scancell Plc(OTC) SCNLF

Market Cap$170.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-73%
5 Year-33%
1 Year+6%
1 Month+2%
$0.14
+0.71%
+0.00Today
Scancell Plc last closing stock price
MetricPriceDate
Last closeUSD 0.142026-10-01
Scancell Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.142026-09-09
1 month+1.88%USD 0.142026-09-01
3 month-49.44%USD 0.282026-06-25
Year to date-2.08%USD 0.142025-12-10
1 year+5.94%USD 0.132025-09-12
3 year-15.06%USD 0.172023-09-19
5 year-32.86%USD 0.212021-09-08
Since inception-72.88%USD 0.522013-07-29

Scancell Plc Financials at a Glance

Market Cap

$170.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£4.71M

Net Income (TTM)

-£21.33M

EPS (TTM)

-$0.02

P/E Ratio

-6.10

Dividend

$0.00

Beta (Volatility)

21.45 (High)

Price

$0.14

Volume

1

Open

$0.15

Previous Close

$0.14

Daily Range

$0.14 - $0.15

52-Week Range

$0.12 - $0.33

Estimated Earnings Date

Feb 4, 2027

SCNLF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Scancell Plc

Scancell Holdings plc is a biopharmaceutical company focused on developing innovative vaccines and antibody-based treatments for significant unmet medical needs in cancer and infectious diseases. The company is advancing several promising therapies through clinical trials, aiming to improve patient outcomes.

Products and Services
  • SCIB1: An ImmunoBody cancer vaccine for metastatic melanoma
  • SCIB2/iSCIB2: A vaccine targeting various solid tumors, including non-small cell lung cancer
  • Modi-1 and Modi-2: Vaccines in development for multiple cancer types, including ovarian and renal cancers
Growth Outlook
  • Recent clinical trials show promising results for SCIB2 against solid tumors
  • Expansion into infectious disease vaccines with SCOV1 and SCOV2 for COVID-19
  • Strong pipeline with multiple candidates in various stages of clinical development
Financial Highlights
  • Recent quarterly revenue of 0, reflecting ongoing investment in R&D
  • Trailing twelve months (TTM) net income of -$25.5 million, indicating significant R&D expenses
  • Cash and cash equivalents of approximately $8.6 million as of the latest quarter
Scancell Holdings plc is positioned in the biotechnology sector, focusing on innovative solutions to combat cancer and infectious diseases. The company's pipeline includes several advanced therapies, which are currently undergoing clinical trials. Despite recent financial challenges, including a net loss, the ongoing development of its product candidates reflects a commitment to addressing critical health issues. The company’s strategic focus on both cancer and infectious diseases may provide significant growth opportunities in the evolving biopharmaceutical landscape.
AI Generated • Sep 26, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Philip John L'Huillier, PhD, MBA

Website

www.scancell.co.uk

Headquarters

Oxford, OX OX4 4GD, GB

SCNLF Financials

Key Financial Metrics (TTM)

Gross Margin

78.45%

Operating Margin

-283.34%

Net Income Margin

-116.98%

Return on Equity

90.29%

Return on Capital

-120.66%

Return on Assets

-35.84%

Earnings Yield

-16.39%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$170.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.21B

Volume

1

Avg. Volume

6.61K

Financials (TTM)

Gross Profit

£2.95M

Operating Income

-£34.05M

EBITDA

-£23.94M

Operating Cash Flow

-£22.73M

Capital Expenditure

-£178.00K

Free Cash Flow

-£22.91M

Cash & ST Invst.

£8.58M

Total Debt

£16.19M

Scancell Plc Performance Analysis

Scancell Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-04-30GBP 6,326,604N/A
20242024-04-30GBP 0N/A
20252025-04-30GBP 6,033,449N/A
20262026-04-30GBP 0N/A
Scancell Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-04-30N/A
Q22024-10-31N/A
Q42025-04-30N/A
Q22025-10-31-100.0%
Scancell Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-04-30GBP -0.02130.3%
20242024-04-30GBP -0.01-51.4%
20252025-04-30GBP -0.0290.6%
20262026-04-30GBP -0.0243.2%
Scancell Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-04-30-19.4%
Q22024-10-31-264.9%
Q42025-04-30101.5%
Q22025-10-31-3300.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

£0.00

N/A

Gross Profit

-£377.27K

+13.1%

Gross Margin

0.00%

N/A

Market Cap

$170.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.80M

N/A

Employees

61

N/A

Net Income

-£5.75M

-125.5%

EBITDA

-£5.46M

-105.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

£8.58M

-34.4%

Total Debt

£16.19M

-18.3%

Accounts Receivable

£4.70M

-16.3%

Inventory

£0.00

N/A

Long Term Debt

£0.00

-100.0%

Short Term Debt

£16.18M

+530.8%

Return on Assets

-35.84%

N/A

Return on Invested Capital

1.59%

N/A

Free Cash Flow

-£7.09M

-6.3%

Operating Cash Flow

-£7.09M

-6.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MLLCFMolecular Partners AG
$4.01+0.00%
IPHYFInnate Pharma S.A.
$1.51+0.00%
NDTPNDT Pharmaceuticals Inc.
$0.40+13.43%
BXPHFBotanix Pharmaceuticals Limited
$0.02+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About SCNLF

What is the current price of Scancell Plc?

Scancell Plc is trading at $0.14 per share.

What is the 52-week range for Scancell Plc?

Over the past 52 weeks, Scancell Plc has traded between $0.12 and $0.33.

How much debt does Scancell Plc have?

As of the most recent reporting period, Scancell Plc reported total debt of £23.21M.

How much cash does Scancell Plc have on hand?

Scancell Plc reported £7.23M in cash and cash equivalents in its most recent financial results.

What is Scancell Plc’s dividend yield?

Scancell Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services